Through this session, we will explore the advantages of incorporating AI and digital pathology for drug and biomarker discovery as part of a long-term CDx partnership. We will also explore potential regulatory challenges in this ever-evolving space.
Learning Objectives
Discuss the importance of a complete development lifecycle of drug and companion diagnostic; Describe a complete development lifecycle of a drug and companion diagnostic; Describe potential regulatory challenges facing AI, Digital Pathology, and CDx development.
